NIKKEI 225
27,782.42+200.76(+0.73%)HANG SENG
26,176.94+703.06(+2.76%)CRUDE OIL
72.78+0.39(+0.54%)GOLD FUTURES
1,816.10+16.40(+0.91%)DOW
34,930.93-127.59(-0.36%)BTC-GBP
28,771.41+411.04(+1.45%)
CureVac N.V. (CVAC)
| Previous close | 52.37 |
| Open | 52.13 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 1000 |
| Day's range | 52.01 - 53.62 |
| 52-week range | 36.15 - 151.80 |
| Volume | 322,336 |
| Avg. volume | 1,431,745 |
| Market cap | 9.831B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.15 |
| Earnings date | 15 Apr 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 67.47 |
- The Telegraph
Questor: our vaccine stocks are fine, but nothing can inoculate airlines against Covid uncertainty
Questor tipped four coronavirus vaccine makers between last August and this April and the black sheep of that family has been CureVac, the German-based but American-listed biotech firm. While shares in BioNTech, Moderna (which we later sold at a large profit) and AstraZeneca have all performed well, especially the former two, those in CureVac have lost more than half their value after it announced disappointing vaccine efficacy last month. Time to throw them into the sharps bin? Much of our inte
- Motley Fool
Can CureVac Win Market Share With Only 48% Vaccine Efficacy?
CureVac (NASDAQ: CVAC) surprised investors a few weeks ago when it announced disappointing data from a trial of its mRNA vaccine candidate. Many expected the German biotech would follow in the footsteps of fellow mRNA vaccine makers Pfizer and Moderna. After the CureVac report, it looked like company's dreams of a spot in the vaccine market were over -- at least in the near term.
- Zacks
Biotech Stock Roundup: ALEC Surges on Deal With GSK, CVAC Down on Study Results & More
The biotech sector was in focus last week on the collaboration news from Alector (ALEC) and pipeline updates from CureVac (CVAC).
